[Diabetes, Conn syndrome and osteoporosis. What is new in diagnosis and therapy?].
Reincke
M
M
Endokrinologie/Diabetologie, Universitätsklinikum Freiburg.
D000236:Adenoma / Q000601:surgery; D000310:Adrenal Gland Neoplasms / Q000601:surgery; D000315:Adrenalectomy; D000328:Adult; D000368:Aged; D003327:Coronary Disease / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications* / Q000601:surgery / Q000628:therapy; D006943:Hyperglycemia / Q000188:drug therapy; D006973:Hypertension / Q000209:etiology*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
D004164:Diphosphonates; D004965:Estrogen Antagonists; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride